LASSBio-1736
LASSBio-1736 is a Cysteine protease inhibitor and antimalarial agent. LASSBio-1736 targets the promastigote form of Leishmania major. LASSBio-1736 can be used in the research of leishmaniasis.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- CAS 番号: 1554691-37-0
- 分子式: C16H11Cl2F3N4O2
- 分子量:419.19
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
生物活性
製品説明
IC50 & Target
[1]|
Leishmania |
体外実験
LASSBio-1736 (up to 100 μM) potently inhibits the growth of Leishmania major promastigotes; additionally, it shows no cytotoxicity against J774 murine macrophages at concentrations up to 100 μM[1].
LASSBio-1736 can penetrate the simulated blood-brain barrier, with a permeability coefficient of 10.63 × 10−6 cm s-1[2].
LASSBio-1736 (5 μM; 0-240 min) exhibits high stability in rat plasma, with a half-life of 28.9 h and only 7.30% metabolic conversion within 240 minutes[2].
LASSBio-1736 potently inhibits the growth of Leishmania major promastigotes with an IC50 of 0.4 μg/mL, and exhibits no cytotoxicity against J774 mouse macrophages[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
体内実験
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c (male)[1]
-
Dosage:30 μmol/kg
-
Administration:i.p.; daily; 28 days
-
Result:Caused a significant decrease in the number of Leishmania amazonensis amastigotes in the mouse ear dermis and lymph nodes compared to glucantime (administered at the same dose and schedule).
Parmacokinetics
化学情報
-
CAS 番号 1554691-37-0
-
分子量 419.19
-
分子式 C16H11Cl2F3N4O2
-
SMILES
O=C(NNC(C1=CC=C(Cl)C=C1Cl)=O)N/N=C/C2=CC=C(C(F)(F)F)C=C2
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
参考文献
[1]. Moraes BS, et al. Leishmanicidal candidate LASSBio-1736, a cysteine protease inhibitor with favorable pharmacokinetics: low clearance and good distribution. Xenobiotica. 2018 Dec;48(12):1258-1267. [Content Brief]
[2]. de Queiroz AC, et al. Pre-clinical evaluation of LASSBio-1491: From in vitro pharmacokinetic study to in vivo leishmanicidal activity. PLoS One. 2022 Jun 6;17(6):e0269447. [Content Brief]
[3]. Moraes BKS, et al. Simple HPLC-UV for the quantification of a new leishmanicidal candidate (E)-1-4(trifluoromethyl) benzylidene)-5-(2-4-dichlorozoyl) carbonylhydrazine (LASSBio-1736) in rat plasma for pharmacokinetics assessment. Biomed Chromatogr. 2016 Jul;30(7):1029-1035. [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)